Skip to Content

Lung Cancer Awareness Month 2026: From Early Detection to Precision Oncology

What cancer nurses need to know 

Irati Rodriguez Matesanz, BSN, MSN, APRN  |  Thoracic Oncology and Clinical Research Nurse Practitioner, City of Hope Atlanta, USA  |  EONS Early Career Nurses Working Group Co-Chair 

November marks Lung Cancer Awareness Month, an opportunity to raise awareness of a disease that remains the leading cause of cancer-related death worldwide. Global estimates for 2024 indicate approximately 2.6 million new lung cancer diagnoses and nearly one in five cancer deaths attributable to lung cancer. Despite this burden, stigma associated with smoking continues to influence public perceptions and can affect patients’ experiences and help-seeking behaviours. [1] 

Tobacco exposure remains the leading preventable risk factor. However, lung cancer also occurs in people who have never smoked. Second-hand smoke, radon, air pollution and occupational exposures, including asbestos and diesel exhaust, contribute to risk. Prevention therefore requires tobacco control and smoking cessation support alongside environmental and occupational risk reduction. 

Prevention and early detection across Europe 

Low-dose computed tomography (LDCT) screening can detect lung cancer at an earlier, potentially curable stage in eligible high-risk populations. Implementation remains uneven across Europe, with established programmes, phased national rollouts and structured pilots operating in different countries. Table 1 provides an illustrative overview; local eligibility criteria and programme status should always be checked against current national guidance. [2,3] 

Table 1. Selected European lung cancer screening initiatives (overview, November 2026) 

Country 

Implementation 

Approach 

Croatia 

National programme 

LDCT for eligible people with substantial smoking exposure. 

England 

National phased rollout 

NHS Lung Cancer Screening Programme; risk assessment followed by LDCT for those meeting criteria. 

Germany 

National programme rollout 

Risk-based LDCT eligibility under national implementation arrangements. 

Poland 

Structured programme / pilot initiatives 

LDCT for eligible high-risk individuals; criteria vary by initiative. 

Czechia 

Structured pilot 

LDCT for high-risk populations. 

Italy 

Regional and structured pilots 

LDCT for high-risk populations; implementation varies. 

Hungary 

Structured pilot 

LDCT for high-risk populations. 

Spain 

CASSANDRA pilot 

Risk-based LDCT screening under a national research initiative. 

Screening is not a substitute for diagnostic assessment. Patients with persistent or concerning symptoms require appropriate evaluation regardless of whether they meet screening eligibility criteria. Nurses can help identify eligible individuals, explain screening benefits and limitations, support smoking cessation and facilitate timely follow-up of abnormal results. 

Lung cancer in people who have never smoked 

An increasing proportion of lung cancer diagnoses occur among people who have never smoked. Some populations, particularly women in parts of Asia, have shown rising age-standardised incidence, although whether absolute incidence is increasing globally remains uncertain. An increasing proportion alone does not prove an increase in absolute risk. [4,5] 

Persistent cough, dyspnoea, chest pain, haemoptysis, unexplained weight loss and fatigue may occur regardless of smoking history. A history of never smoking should not delay appropriate investigation. Nurses can challenge the misconception that lung cancer affects only people who smoke and advocate for prompt evaluation when symptoms persist. 

Lung adenocarcinomas in never-smokers are more likely to harbour certain oncogenic driver alterations, particularly EGFR mutations and ALK rearrangements. Prevalence varies by ancestry, geography and tumour characteristics. These biological differences reinforce the importance of comprehensive molecular profiling rather than assumptions based on smoking history alone. [4–6] 

From histology to precision treatment 

Lung cancer comprises biologically distinct diseases. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of cases; small cell lung cancer (SCLC) accounts for roughly 10–15%. Less common pulmonary neuroendocrine neoplasms include carcinoid tumours and large cell neuroendocrine carcinoma. Classification matters because management, prognosis and treatment-related risks differ. 

Comprehensive biomarker testing is central to treatment planning in advanced nonsquamous NSCLC and is relevant in selected squamous and earlier-stage settings. Next-generation sequencing (NGS) of tumour tissue, sometimes complemented by plasma circulating tumour DNA (ctDNA), can identify alterations involving EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, ERBB2 (HER2) and other genes. PD-L1 immunohistochemistry provides additional information for immunotherapy decisions. A negative plasma result does not exclude an actionable alteration and may require tissue-based testing. [6,7] 

Where clinically feasible, molecular results should inform the initial systemic treatment decision, particularly before initiating immunotherapy in advanced nonsquamous NSCLC. Tissue and plasma testing may be coordinated in parallel to reduce delays. Nurses contribute by tracking specimens and results, supporting patient understanding and escalating gaps that could delay treatment. 

Therapeutic advances have changed outcomes for many patients. Targeted therapies benefit selected oncogene-driven NSCLCs, while immune checkpoint inhibitors have improved outcomes in several NSCLC and SCLC settings. Bispecific T-cell engagers, including tarlatamab, are adding new options in SCLC. However, benefits vary across populations and treatment lines, and significant unmet needs remain. Nurses must remain familiar with distinct toxicity profiles, from targeted-therapy adverse effects and immune-related toxicities to cytokine release syndrome and neurological events associated with T-cell–engaging treatments. [8–11] 

Key takeaways for cancer nurses 

Challenge stigma and promote awareness. Lung cancer can affect anyone. Use non-judgemental language and support patients irrespective of smoking history. 

Recognise symptoms and facilitate early diagnosis. Persistent or concerning symptoms warrant evaluation, including in people who have never smoked. 

Advocate for prevention and equitable screening. Promote tobacco cessation, risk reduction, appropriate LDCT screening and reliable follow-up. 

Understand biomarker testing. Help coordinate comprehensive profiling and explain why results may determine the treatment pathway. 

Stay informed about emerging therapies and toxicities. Keep skills current as targeted agents, immunotherapies and bispecific T-cell engagers reshape clinical care. 

References 

1. International Agency for Research on Cancer (IARC). GLOBOCAN 2024 global cancer estimates. IARC/WHO. 

2. Lung Cancer Screening in Adults: State-of-the-Art and Policy Mapping (2025). Cancers. 2026. PMID: 41749848. 

3. Implementation of the NHS England Lung Cancer Screening Programme over 5 years. Nature Medicine. 2026. doi:10.1038/s41591-026-04292-y. 

4. Murphy C, Pandya T, Swanton C, Solomon BJ. Lung Cancer in Nonsmoking Individuals: A Review. JAMA. 2025. 

5. Zhao J, Li M, Niu L, et al. Lung cancer in non-smoking women: from risk factors to precision therapy. Cancer Metastasis Reviews. 2025. 

6. Devarakonda S, Li Y, Martins Rodrigues F, et al. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. Journal of Clinical Oncology. 2021. 

7. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer. Clinical Practice Guidelines in Oncology. Updated September 22, 2026. 

8. Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New Promises and Challenges in the Treatment of Advanced Non-Small-Cell Lung Cancer. Lancet. 2024. 

9. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine. 2020. 

10. Ross JS, Hockemeyer KG, Redin E, Rudin CM. The Changing Therapeutic Landscape of Small-Cell Lung Cancer. Lancet. 2026. 

11. Pérol M, Yoshida T, Ahn MJ, et al. Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. 2026. 

 

AI Disclaimer: This article was independently developed by the author. ChatGPT (OpenAI) was used solely to assist with language editing, clarity, and formatting. The author remains responsible for its content.